Evidence map›Paper›PMID 35729539›Full record

ArticleRespiratory research2022

Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea.

Marta Marin-Oto, David Sanz-Rubio, Fernando Santamaría-Martos, Ivan Benitez, Ana L Simon, Marta Forner, Pablo Cubero, Ana Gil, Manuel Sanchez-de-laTorre, Ferran Barbe and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Marta Marin-OtoTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain.ORCID http://orcid.org/0000-0003-0777-3850
David Sanz-RubioTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain.ORCID http://orcid.org/0000-0002-5228-248X
Fernando Santamaría-MartosRespiratory Department, Hospital Arnau de Vilanova, IRB-Lleida, Lleida, Spain.
Ivan BenitezRespiratory Department, Hospital Arnau de Vilanova, IRB-Lleida, Lleida, Spain.
Ana L SimonTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain.
Marta FornerTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain.
Pablo CuberoTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain.
Ana GilTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain.
Manuel Sanchez-de-laTorreRespiratory Department, Hospital Arnau de Vilanova, IRB-Lleida, Lleida, Spain.
Ferran BarbeRespiratory Department, Hospital Arnau de Vilanova, IRB-Lleida, Lleida, Spain.ORCID http://orcid.org/0000-0002-2340-8928
José M MarinTranslational Research Unit, Aragón Health Research Institute, Zaragoza, Spain. jmmarint@unizar.es.ORCID http://orcid.org/0000-0001-9096-2294
Instituto de Investigación Sanitaria Aragón · ESHospital Arnau de Vilanova · ESInstituto de Salud Carlos III · ESUniversidad de Zaragoza · ES

Funding

Instituto Salud Carlos III, Spanish Ministry of Health, Madrid, Spain PI12/02175, PI15/01940 and PI18/01524
6 · The paper itself

Abstract

backgroundHypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-inflammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap.

methodsPlasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers [HNS], 84 healthy smokers [HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap).

resultsAfter adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (- 12.5%, p = 0.005), COPD (- 14.8%, p < 0.001) and OSA-COPD overlap (- 12.3%, p = 0.02) compared with HNS. There were no differences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change significantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased significantly.

conclusionsThe levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD.

Indexed as

Pulmonary Disease, Chronic ObstructiveSleep Apnea, ObstructiveAntigens, NeoplasmContinuous Positive Airway PressureHumansHypoxiaMitogen-Activated Protein KinasesReceptor for Advanced Glycation End ProductsAntigens, NeoplasmMitogen-Activated Protein KinasesMOK protein, humanReceptor for Advanced Glycation End ProductsChronic obstructive pulmonary diseaseObstructive sleep apnoeaSmokerssRAGE

Identifiers

PMID35729539
PMCPMC9210762
OpenAlexW4283266599

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.